Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Investigational triple agonist of GIP, GLP-1 and glucagon receptors

Retatrutide

An investigational incretin/glucagon-receptor agonist in Phase 3 development. It is not an FDA-approved drug product. PubChem does not currently assign a discrete CID to the structure.

Also listed as: LY3437943, LY-3437943

Chemical identity

Compound class
Investigational triple agonist of GIP, GLP-1 and glucagon receptors
Sequence
Unknown
Molecular formula
Unknown
Molecular weight
4731.33 g/mol (average mass, widely cited for the free base)
CAS number
2381089-83-2
PubChem CID
Unknown
Research categories
Incretin analogues, Investigational drug substances

United States regulatory status

Investigational

  • No approved United States product in Drugs@FDA as of this review.
  • CAS 2381089-83-2 is the identifier used in DrugBank and related registries.
  • A Phase 2 obesity trial is published in NEJM (2023). Sponsor Phase 3 topline disclosures in the TRIUMPH programme are not a listing decision and are not an approved label.
  • Not interchangeable with semaglutide or tirzepatide, which have different receptor profiles and approved products.

Regulatory status describes how a substance is classified. It is not a safety assessment, and it says nothing about the quality of any particular material.

Evidence overview

2 records in this file

  • CLINICAL TRIAL2

Research areas. Investigational-drug Phase 2; Investigational-drug Phase 3.

Publication span. 2023–2026.

Open the evidence file

What we know

  • Jastreboff et al. 2023 (NEJM) is a published Phase 2 obesity trial of investigational retatrutide.
  • Lilly has issued Phase 3 TRIUMPH-1 topline disclosures. Those are sponsor communications, not a peer-reviewed paper and not an approval.
  • No Drugs@FDA approved product as of this review. Not interchangeable with semaglutide or tirzepatide.

Editorial reading of the records below, labelled as Therapept analysis. How records are built

What remains uncertain

  • The full peer-reviewed TRIUMPH clinical package, including estimands and adverse-event tables.
  • Whether, and when, FDA will license a product — a Phase 3 topline is not a listing decision.

Sources

  1. PubChem — Retatrutide
  2. Drugs@FDA — approved drug products

Last reviewed 12 September 2026 · Compiled by Therapept Editorial · How these records are built